For step-by-step instructions on injecting Dupixent, you can view training videos on Dupixent’s manufacturer website. There are also injection instructions in Dupixent’s prescribing information.

Now dupilumab (Dupixent) has come along, and for those with the chronic ... My messaging to pediatricians, as I did full pediatrics training years ago at CHOP [Children’s Hospital of Philadelphia] [in ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...